Psychedelic Research Bulletin: January 2023 Post published:February 15, 2023 Post category:Psychedelics Research Review
Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability Post published:February 14, 2023 Post category:Press Release
Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results Post published:February 14, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Post published:February 14, 2023 Post category:Press Release
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv Post published:February 14, 2023 Post category:Press Release
Silo Pharma Announces Filing of Patent for Treatment of Alzheimerās Post published:February 13, 2023 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Post published:February 10, 2023 Post category:Press Release
Establishing the Psychedelic Research Center Consortiumā Post published:February 10, 2023 Post category:2022 Year in Review
Key Psychedelic Research Themes in 2022 Post published:February 9, 2023 Post category:2022 Year in Review
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements Post published:February 8, 2023 Post category:Press Release